Foodborne Diseases Treatment Market Outlook to 2023: Key Players Bayer AG (Germany), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland)

Global Foodborne diseases cover a broad spectrum of illnesses that are affecting the people worldwide. These diseases are due to the intake of food contaminated with harmful microorganisms or chemicals. The contamination occurs from any way either soil, water or air. The most common foodborne infections are caused by three bacteria campylobacter, salmonella, and E.coli and by a group of viruses called calicivirus. Clinical symptoms of foodborne diseases seen in gastro intestinal tract. Symptoms include vomiting, diarrhea, and abdominal pain. In some cases, such diseases can also have neurological, gynecological, immunological and other symptoms. Common foodborne diseases include botulism, salmonellosis, traveler’s diarrhoea, gastroenteritis, tapeworm infection and hepatitis A, among others. Global foodborne diseases treatment market is driven by the increasing incidence of foodborne diseases worldwide.

Global Foodborne Diseases Treatment Market
Increase in R&D investment, growing awareness about foodborne disease symptoms due to initiatives of government and non-government organizations such as WHO, and lack of hygiene conditions are boosting the foodborne diseases treatment market worldwide. However, the high cost of R&D investment for development of anti microbial and stringent, time-consuming regulatory procedures are expected to hinder the foodborne diseases market.

Request Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-PBI-HnM-3240

Foodborne diseases treatment market has been segmented based on disease, drug class, and distribution channel

Based on drug class, foodborne diseases treatment market is segmented into
Antibiotics
Anti Diarrhea
Fluids and Electrolyte Replenishers
Vaccines
Others

Based on disease, foodborne diseases treatment is segmented into
Botulism
Traveler’s Diarrhea
Gastroenteritis
Toxoplasmosis
Others

Based on route of administration, foodborne diseases treatment market is segmented into
Parenteral
Oral
Others

Based on distribution channel, foodborne diseases treatment market is segmented into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-PBI-HnM-3240

Foodborne diseases treatment market is expected to grow at significant CAGR during the forecast period. According to the findings of WHO – “Estimates of the global burden of foodborne diseases” 2015, almost 1 in every10 people fall ill yearly due to contaminated food consumption and 420,000 deaths occour as a result. Market players are adopting drug developments and collaborations as key market strategies.

Geographically Foodborne Diseases Treatment Market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America foodborne diseases treatment market is expected to grow at notable rates due to increase in the prevalence of foodborne diseases such as botulism and toxoplasmosis, and increase in R&D investment by companies on antibiotics and vaccines. Asia Pacific and Africa regions are projecting lucrative opportunity for foodborne diseases treatment market owing to increase in the incidence of foodborne diseases in these regions. According to WHO estimates 2015, Africa and South East Asia regions have the highest incidence and death rates, including children under the age of 5 years. Europe is expected to show significant growth rate owing to increase in R&D investment and healthcare spending.

Some of the market players in foodborne diseases treatment market are Bayer AG (Germany), Johnson & Johnson Services Inc., (U.S.), Merck & Co., Inc. (U.S.), GlaxoSmithKline plc (U.K), Novartis AG (Switzerland), XOMA Corporation (U.S.), AlphaVax, Inc. (U.S.), Molecular Targeting Technologies, Inc. (U.S.), and Morphotek Inc. (U.S.) to name a few

Buy This Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-PBI-HnM-3240/

In 2015, January, Valneva SE, entered a purchase and sale with Crucell Holland B.V. in order to acquire Crucell Sweden AB and privileges and licenses of dukoral vaccine to treat cholera and traveler’s diarrhea

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
https://www.qurateresearch.com/
IN +919881074592
info@qurateresearch.com

This release was published on openPR.